-- Randy Dotinga
TUESDAY, July 5 (HealthDay News) -- A drug designed to treat
certain patients with non-small cell lung cancer boosts survival
time without progression of cancer by several months, according to
a new study.
The findings reveal that the drug, known as erlotinib (brand
name Tarceva), doesn't just boost lifespan, said Dr. Neal E. Ready,
associate professor of medical oncology at Duke Cancer Institute,
who was not involved with the study. "What you really get is a
prolonged period of time when the cancer is under control and
someone has a really good quality of life."
This study is the first of its kind to look at Western patients.
"Although a growing body of evidence has been emerging about this
type of lung cancer, almost all of the studies have been conducted
in Asian patients, a group that historically has had significantly
different results to [non-small cell lung cancer] therapy compared
to Western populations," said principal investigator Dr. Radj
Gervais, of the Centre Francois Baclesse in Caen, France, in a news
release from the International Association for the Study of Lung
Cancer. The association is hosting the World Conference on Lung
Cancer in Amsterdam, where the study results were scheduled for
The study of the drug is a phase 3 study. That means it's in the
final of three stages of testing that drugs undergo before they can
be approved for treatment of a specific disease.
The researchers randomly assigned 174 patients to either
erlotinib or platinum-based chemotherapy. Preliminary results
showed that about 55 percent of patients responded to the drug,
compared to nearly 11 percent to chemotherapy. Patients lived
without progression of cancer for 9.4 months with the drug compared
to 5.2 months for those who received chemotherapy.
And the median survival was 22.9 months for those who took the
drug compared to 18.8 months for those on chemotherapy, the
"Our results showed that first-line erlotinib nearly doubled progression-free survival; that's a significant improvement over chemotherapy, with a better tolerability profile," Gervais said in the news release.
Commenting on the findings, Ready pointed out that the research
is important because it shows the value of targeting treatment
towards patients with specific types of non-small cell cancer. "In
oncology as a field, we're trying to move to identify the right
treatment for the right patient," he said.
Erlotinib's side effects -- including an acne-type rash and
diarrhea -- are easier to control than those of chemotherapy, he
added. As for expense, Ready noted, oral therapies, like this one,
tend to be as costly or less expensive than chemotherapy,
considering that they cause fewer side effects that need to be
Because this study was presented at a medical meeting, the data
and conclusions should be viewed as preliminary until published in
a peer-reviewed journal.
For more about
lung cancer, visit the U.S. National Library of Medicine.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.